Review Test Submission: Final Exam - Week 11
User +A1
Course DNRS-6630-5/NURS-6630N-5/NURS-6630C-5/NURS-6630F-5/DNRS-
6630F-5- Approaches to Treatment-2021-Summer-QTR-Term-wks-1-thru-
11-(05/31/2021-
08/15/2021)-
...
Review Test Submission: Final Exam - Week 11
User +A1
Course DNRS-6630-5/NURS-6630N-5/NURS-6630C-5/NURS-6630F-5/DNRS-
6630F-5- Approaches to Treatment-2021-Summer-QTR-Term-wks-1-thru-
11-(05/31/2021-
08/15/2021)-PT27
Test Final Exam - Week 11
Started 8/12/21 8:32 AM
Submitted 8/12/21 10:06 AM
Due Date 8/16/21 1:59 AM
Status Completed
Attempted Score 92 out of 100 points
Time Elapsed 1 hour, 34 minutes out of 2 hours and 30 minutes
Results Displayed Feedback
Question 1
L. J. is a 55-year-old male who attended a funeral and found himself laughing
during the service, but later that evening he was irritated with himself for what he
had done. His wife said this was abnormal behavior and took him to his doctor to
be evaluated. After L. J.’s MRI was reviewed, he was diagnosed with
frontotemporal dementia. Which medication is recommended to help L. J. with
his emotional outbursts?
A . Memantine
B . Escitalopram
C . Donepezil
D . Risperidone
Response Feedback: under Treatment subtitle: “The behavioral features are
sometimes helped by SSRIs, and these are the best-studied treatments for these
disorders.”
Question 2
When can buprenorphine be initiated in a patient who is suffering from an opioid
overdose?
A . As soon as the patient is stabilized
B . It should be administered as soon as you find the patient unconscious
C . Right after naloxone is administered to prevent the patient from going back
into opioid overdose
D . When the patient is experiencing mild-to-moderate symptoms of withdrawal
Response Feedback: “To avoid this problem, the initial buprenorphine dose
should not be administered until the patient demonstrates mild-to-moderate
symptoms of withdrawal.”
Question 3
Of the following neurotransmitters, which one(s) are known to be severely
disrupted in the disease Dementia with Lewy Bodies?
I. Acetylcholine
II. Glutamate
III. Dopamine
IV. GABA
V. Norepinephrine
A . II only
B . III only
C . I and II
D . I and III
Response Feedback: under pathophysiology subtitle: “It is clear that both the
cholinergic and dopaminergic neurotransmitter systems are severely disrupted.”
Question 4
Choose the correct statement regarding medications used for alcoholism
A . Disulfiram: NMDA receptor antagonist & GABAA agonist
B . Naltrexone: µ-opioid receptor antagonist that reduces the
reinforcement/euphoria produced by alcohol
C . Acamprosate: enhances the effect of the inhibitory neurotransmitter gammaaminobutyric acid on the GABA receptors by binding to a site that is distinct from
the GABA binding site in the central nervous system.
D . Lorazepam: inhibits alcohol dehydrogenase, leading to a buildup of
acetaldehyde
Response Feedback: Table 15-3 has the three MOAs listed for the FDA-approved
treatments of alcoholism.
Question 5
Patient is a 75-year-old female with a confirmed diagnosis of Alzheimer’s Disease.
She is currently on Donepezil 10 mg daily. She is accompanied to your clinic today
by her daughter, who informs you that her mother has recently had an increase in
depressive symptoms. She has no history of mood disorders. She has a history of
hypertension and tonic-clonic seizures, but both are
[Show More]
.png)
